Skip to main content

Blood And Marrow Transplantation

2
Pipeline Programs
3
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
1
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
2100%
+ 1 programs with unclassified modality

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Targazyme
TargazymeCA - Carlsbad
1 program
1
Fludarabine, Clofarabine, Busulfan, ATG, TBIPhase 1/21 trial
Active Trials
NCT01983761Unknown25
Kite Pharma
Kite PharmaCA - El Segundo
1 program
1
CidofovirPhase 1Small Molecule1 trial
Active Trials
NCT01816646Completed6Est. Dec 2016
Gilead Sciences
Gilead SciencesFOSTER CITY, CA
1 program
CidofovirPHASE_1Small Molecule

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
TargazymeFludarabine, Clofarabine, Busulfan, ATG, TBI
Kite PharmaCidofovir

Clinical Trials (2)

Total enrollment: 31 patients across 2 trials

NCT01983761TargazymeFludarabine, Clofarabine, Busulfan, ATG, TBI

Study of ASC-101 in Patients With Hematologic Malignancies Who Receive Dual-cord Umbilical Cord Blood Transplantation

Start: Nov 201325 patients
Phase 1/2Unknown

Intravesical Cidofovir for Hemorrhagic Cystitis

Start: Sep 2013Est. completion: Dec 20166 patients
Phase 1Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

Small Molecule is the dominant modality (100% of programs)
3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.